HEM Pharma Inc
376270
Company Profile
Business description
HEM Pharma Inc is a microbiome-specialized healthcare company that operates a customized healthcare business and an LBP (Live Biotherapeutic Products) discovery platform business utilizing PMAS (Personalized Pharmaceutical Metal-Analytical Screening), a gut microbiome simulation technology. Its technology includes PMAS, MBR, Multi-omics, Microbiome, and Metabolome.
Contact
558, Handong-ro, Heunghae-eup
F102ho, 102ho
Gyeongsangbuk-do
Buk-gu
Pohang-si
KORT: +82 18994258
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
94
Stocks News & Analysis
stocks
Cheap ASX share may have more room to run
Shares are cheap despite rebounding share price, yet risks remain.
stocks
ASX listed media giant drives strong earnings growth
Digital growth drives earnings beat for media share.
stocks
ASX real estate platform outperforms yet questions remain
Valuation remains a key concern despite strong August reporting.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,421.80 | 15.60 | -0.17% |
| CAC 40 | 8,714.93 | 15.22 | 0.17% |
| DAX 40 | 26,319.45 | 179.32 | 0.69% |
| Dow JONES (US) | 54,036.93 | 151.83 | 0.28% |
| FTSE 100 | 10,901.09 | 33.20 | 0.31% |
| HKSE | 25,866.51 | 198.48 | 0.77% |
| NASDAQ | 26,690.62 | 342.26 | 1.30% |
| Nikkei 225 | 66,890.30 | 1,283.59 | 1.96% |
| NZX 50 Index | 13,888.24 | 64.11 | 0.46% |
| S&P 500 | 7,757.64 | 47.68 | 0.62% |
| S&P/ASX 200 | 9,231.40 | 18.20 | -0.20% |
| SSE Composite Index | 3,948.72 | 8.68 | 0.22% |